Johnson & Johnson Stock Valuation: Undervalued on Cash Flow or Overpriced on Earnings

Johnson & Johnson's (JNJ) stock has shown significant growth over the past five years, returning 85.7%. However, a closer look at the company's valuation reveals conflicting signals. The Discounted Cash Flow (DCF) model suggests that JNJ is undervalued by 26.7%, with an intrinsic value of around $364 per share.

This discrepancy arises from the DCF's focus on long-term cash generation versus the market-based multiples, which are influenced by earnings power. The P/E ratio, a key metric for pharmaceutical companies, indicates that JNJ is overvalued compared to its peers and the broader industry average.

Johnson & Johnson's pipeline of new medicines, particularly in neuropsychiatry and pulmonary arterial hypertension, may justify the current premium. However, any setbacks or increased competition could impact future cash flows and change the valuation picture.